Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

OBESITY

GLP1 receptor agonist overcomes SGLT2 inhibitor-related overeating

Nature Reviews Endocrinology volume 18, pages 523–524 (2022)Cite this article

Subjects

Sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment affects central regulation of appetite and satiety, which results in increased carbohydrate intake. It has now been demonstrated that these effects might be blunted by combining SGLT2 inhibitors with glucagon-like peptide 1 receptor agonists to further facilitate weight loss in patients with type 2 diabetes mellitus.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Müller, T. D., Blüher, M., Tschöp, M. H. & DiMarchi, R. D. Nat. Rev. Drug Discov. 21, 201–223 (2022).

  2. Blüher, M. Nat. Rev. Endocrinol. 15, 288–298 (2019).

  3. Saper, C. B., Chou, T. C. & Elmquist, J. K. Neuron 36, 199–211 (2002).

  4. Stice, E., Spoor, S., Bohon, C., Veldhuizen, M. G. & Small, D. M. J. Abnorm. Psychol. 117, 924–935 (2008).

  5. Brown, E., Heerspink, H. J. L., Cuthbertson, D. J. & Wilding, J. P. H. Lancet 398, 262–276 (2021).

  6. Horie, I. et al. Diabetes Res. Clin. Pract. 135, 178–184 (2018).

  7. van Ruiten, C. C. et al. J. Clin. Endocrinol. Metab. 107, e2590–e2599 (2022).

  8. van Ruiten, C. C. et al. Diabetes Obes. Metab. https://doi.org/10.1111/dom.14732 (2022).

Download references

Author information

Authors and Affiliations

  1. Helmholtz Institute for Metabolic, Obesity and Vascular Research, University of Leipzig, Leipzig, Germany

    Matthias Blüher

  2. Department of Endocrinology, Nephrology, Rheumatology, University of Leipzig, Leipzig, Germany

    Matthias Blüher

Authors
  1. Matthias Blüher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Blüher.

Ethics declarations

Competing interests

M.B. received honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Lilly, Novo Nordisk, Novartis, Pfizer and Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blüher, M. GLP1 receptor agonist overcomes SGLT2 inhibitor-related overeating. Nat Rev Endocrinol 18, 523–524 (2022). https://doi.org/10.1038/s41574-022-00722-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-022-00722-2

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research